"UPMC Heart and Vascular Institute at UPMC Mercy is located in Pittsburgh, Pa. Visit our website to learn more about the conditions we treat and the services we offer. Schedule your appointment today. UPMC is committed to protecting our communities from the spread of COVID-19. We continue to require people who come to any UPMC facility to wear a facemask that covers their nose and mouth and to practice other preventative efforts like social distancing, even if fully vaccinated."

During the past decade, University of Pittsburgh Cardiovascular Institute conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Pittsburgh Cardiovascular Institute" #1 sponsor was "Point Biomedical" with 5 trials, followed by "University of Pittsburgh" with 5 trials sponsored, "United Therapeutics" with 2 trials sponsored, "W.L.Gore & Associates" with 2 trials sponsored and "Actelion" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Pittsburgh Cardiovascular Institute" #1 collaborator was "EP Research funds" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "University of Pittsburgh" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "University of Pittsburgh Cardiovascular Institute" are "Coronary Artery Disease" (5 trials), "Atrial Fibrillation" (4 trials), "Pulmonary Arterial Hypertension" (3 trials), "Heart Failure" (2 trials) and "Acute Myocardial Infarction" (1 trials). Many other conditions were trialed in "University of Pittsburgh Cardiovascular Institute" in a lesser frequency.

Most popular intervention types in "University of Pittsburgh Cardiovascular Institute" are "Drug" (11 trials), "Device" (6 trials), "Other" (3 trials), "Biological" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "PB127 for Injectable Suspension" (2 trials), "PB127 for injectable suspension" (2 trials), "AccuCinch Ventricular Restoration System" (1 trials) and "GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Pittsburgh Cardiovascular Institute" are 22 trials for "All" genders.

Currently, there are NaN active trials in "University of Pittsburgh Cardiovascular Institute". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in University of Pittsburgh Cardiovascular Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in University of Pittsburgh Cardiovascular Institute, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".